| Edition |
1. Auflage. |
| Description |
1 electronic resource (84 pages ). |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
|
data file |
| Series |
MIPLC studies ; volume 20 |
|
MIPLC studies ; volume 20.
|
| Note |
Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012. |
| Bibliography |
Includes bibliographical references (pages 77-84). |
| Note |
Description based on print version record; resource not viewed. |
| Contents |
Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices. |
|
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German. |
|
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others. |
| Summary |
Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20. |
| Language |
English. |
| Subject |
Drugs -- Patents -- Economic aspects -- European Union countries.
|
|
Patent medicines -- Law and legislation -- European Union countries.
|
|
Patent medicines -- European Union countries -- Case studies.
|
|
Patent medicines. (OCoLC)fst01054844
|
|
Patent medicines -- Law and legislation.
(OCoLC)fst01054849
|
|
European Union countries. (OCoLC)fst01269470
|
|
Médicaments -- Brevets d'invention.
|
|
LAW -- Commercial -- General.
|
| Genre/Form |
Case studies. (OCoLC)fst01423765
|
| Other Form: |
Print version: Patent strategy in pharmaceutical industry Baden-Baden : Nomos, 2014. 9783848709915 (DLC) 2015372690 |
| ISBN |
3848709910 |
|
9783848709915 |
|
9783845251288 |
|
384525128X |
| Standard No. |
AU@ 000056062506 |
|
AU@ 000062534616 |
|
DEBSZ 431647895 |
|
